Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 3.5% – Time to Buy?

Posted by Donald Scott on Jan 18th, 2025

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) traded up 3.5% during trading on Friday . The company traded as high as $1.50 and last traded at $1.48. 95,132 shares changed hands during trading, a decline of 76% from the average session volume of 388,412 shares. The stock had previously closed at $1.43.

Wall Street Analyst Weigh In

Separately, Maxim Group reduced their target price on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

View Our Latest Report on TOVX

Theriva Biologics Stock Up 3.5 %

The company has a market capitalization of $4.11 million, a PE ratio of -0.04 and a beta of 1.23.

Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($6.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.25) by ($0.56).

Hedge Funds Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP purchased a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics as of its most recent filing with the Securities & Exchange Commission. 6.17% of the stock is currently owned by institutional investors.

Theriva Biologics Company Profile

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.